SynthesisClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Efficacy and Safety of Indobufen in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Synthesis in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeIndobufen reversibly inhibits platelet aggregation and has potential efficacy in acute coronary syndrome and long-term cardiovascular prevention. As an alternative treatment for patients intolerant to other antiplatelet drugs, evidence-based medicine is insufficient. The purpose of this study was to evaluate the efficacy and safety of indobufen therapy in patients with coronary artery disease, and to provide reference for expanded clinical use.MethodsWe conducted a systematic review and meta-analysis of studies from the establishment of PubMed, EMBASE and other databases until their publication on November 21, 2024 The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE), the primary safety index was the rate of hemorrhage of the Academic Research Consortium type 2, 3, or 5. The risk of ischemic stroke and myocardial infarction were used as the secondary indexes.ResultsThis meta-analysis included eight studies with a total of 13,545 patients. According to subgroup analysis, there was no significant difference in the incidence of unconscious-cerebrovascular events between indobufen monotherapy and dual antiplatelet agents (OR 1.02, 95%CI 0.84-1.23,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.